Opinion|Videos|September 10, 2024
Administering GPRC5D therapy: Dosing and Monitoring for CRS & ICANS
Author(s)Larysa Sanchez, MD, Samantha Shenoy, MSN, NP
Experts explain the administration of step-up and treatment doses for GPRC5D at your institution, including whether they are given in clinic or in the community, and will discuss how patients are monitored for cytokine release syndrome and immune effector cell–associated neurotoxicity syndrome during the step-up phase.
Advertisement
Episodes in this series
Video content above is prompted by the following:
How are the step-up and treatment doses for GPRC5D administered at your institution? Are they administered in your clinic or in the community?
- How are patients monitored for cytokine release syndrome and immune effector cell–associated neurotoxicity syndrome during step-up dosing?
Advertisement
Related to this article
In a randomized trial, 73% of relatives offered navigation completed genetic testing within 6 months vs 51% of those who received a family letter.
In observation of National PA Week, Moffitt PA Mark Honor details top-of-license nursing collaboration and outpatient end-stage hematology care.
Adding atezolizumab to adjuvant FOLFOX halved the risk of recurrence or death in ATOMIC, with more grade 3 to 4 adverse events.
Real-time check-ins from patients with MBC showed quality of life dipped when depression, anxiety, or fatigue rose above usual levels.
FDA approves tucatinib maintenance with trastuzumab and pertuzumab for HER2+ breast cancer based on HER2CLIMB-05.
In observation of National PA Week, Moffitt PA Mark Honor discusses the expansion of APPs and key collaboration strategies for oncology nurses.
Beth Faiman details the new IMS/IMWG consensus definition of cure for multiple myeloma, requiring 5 years of treatment-free remission.
Advertisement
Advertisement
Trending on Oncology Nursing News
1
Navigation Boosts Cascade Genetic Testing in Relatives of BRCA Carriers
2
Multidisciplinary Support for Patients with Metastatic Triple-Negative Breast Cancer
3
Managing Oral and Ocular Toxicities in Metastatic Triple-Negative Breast Cancer
4
FDA Approves Atezolizumab Plus Chemo for Stage 3 dMMR Colon Cancer
5